HilleVax, Inc.’s (NASDAQ:HLVX) Quiet Period To End on June 8th

HilleVax’s (NASDAQ:HLVXGet Rating) quiet period will end on Wednesday, June 8th. HilleVax had issued 11,765,000 shares in its initial public offering on April 29th. The total size of the offering was $200,005,000 based on an initial share price of $17.00. During the company’s quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of research firms recently commented on HLVX. SVB Leerink began coverage on HilleVax in a report on Tuesday, May 24th. They issued an “outperform” rating and a $30.00 price target on the stock. Stifel Nicolaus began coverage on shares of HilleVax in a report on Tuesday, May 24th. They issued a “buy” rating and a $34.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of HilleVax in a research report on Tuesday, May 24th. They set an “overweight” rating and a $24.00 target price for the company. Finally, Guggenheim began coverage on shares of HilleVax in a report on Tuesday, May 24th. They issued a “buy” rating and a $40.00 price target on the stock.

Shares of NASDAQ:HLVX traded up $0.17 during trading on Wednesday, reaching $10.05. The company’s stock had a trading volume of 93,398 shares, compared to its average volume of 171,268. HilleVax has a 12 month low of $8.82 and a 12 month high of $20.95.

About HilleVax (Get Rating)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Read More

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.